Amgen 2009 Annual Report Download - page 7

Download and view the complete annual report

Please find page 7 of the 2009 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

Approved
Aranesp® (darbepoetin alfa)
Anemia caused by concomitant chemotherapy in
non-myeloid malignancies
Aranesp®
Anemia of chronic kidney failure
Enbrel® (etanercept)
Ankylosing spondylitis (arthritis of the spine)
ENBREL
Chronic moderate-to-severe plaque psoriasis
ENBREL
Moderate-to-severe polyarticular juvenile idiopathic arthritis
ENBREL
Moderate-to-severe rheumatoid arthritis
ENBREL
Psoriatic arthritis
EPOGEN® (Epoetin alfa)
Anemia of end-stage renal disease
Mimpara® (cinacalcet) (EU)
Primary hyperparathyroidism (intractable)
Neulasta® (pegfi lgrastim)
Chemotherapy-induced neutropenia
NEUPOGEN® (Filgrastim)
Neutropenia (multiple indications)
Nplate® (romiplostim)
Adult chronic immune thrombocytopenic purpura
Sensipar®/Mimpara® (cinacalcet)
Hypercalcemia of parathyroid carcinoma
Sensipar®/Mimpara®
Secondary hyperparathyroidism in end-stage renal disease
Vectibix® (panitumumab)
Metastatic colorectal cancer with disease progression on
or following standard chemotherapy
Modalities
Oral/Small
Molecule
Protein/
Peptibody
Antibody
A Year of Innovative Research and
Important Clinical Milestones
■ Released data from three pivotal phase 3 studies
of denosumab in patients with metastatic bone
disease in breast cancer and prostate cancer
and patients with a variety of solid tumors or
multiple myeloma.
■ Announced results from two pivotal phase 3
trials evaluating Vectibix® (panitumumab) in
combination with chemotherapy in fi rst- and
second-line treatment in patients with metastatic
colorectal cancer.
■ Progressed clinical trials, with more than 35,000
patients in more than 50 countries enrolled as
of year-end.
■ Exercised option to an exclusive worldwide
license (excluding Japan) to Cytokinetics’ cardiac
contractility program, which includes omecamtiv
mecarbil, a novel small molecule activator of
cardiac myosin for the treatment of heart failure
that Amgen is developing in collaboration with
the company.
■ Entered an agreement with Array BioPharma
granting Amgen exclusive worldwide rights to an
investigational type 2 diabetes treatment currently
in phase 1 trials.
■ Began human trials of a novel fully human monoclonal
antibody for the treatment of hypercholesterolemia.
Amgen 2009 Annual Report ■ 5